Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RACE: Ribociclib plus Endocrine Therapy in HR+/HER2- Early Breast Cancer
NCT07423611Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2026
- Primary completion
- Oct 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ribociclib in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Circulating Tumor DNA Negativity Rate at 3 years. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07423611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07423611.